On Aug. 5, 2020, AXIM Biotechnologies announced the development, patent filing and Emergency Use Approval (EUA) filing of NeuCovix-HTTM, a high throughput (HT) patent-pending diagnostic test that measures levels of functional antibodies in plasma or serum that neutralize SARS-CoV-2, the virus that causes COVID-19.

Unlike serology tests for COVID-19 that qualitatively detect antibodies to the virus, NeuCovix-HTTM quantitatively measures functional antibodies that block binding of the virus to host cell receptors.